ArticleEndocrine oncology (Bristol, England)2025
Malignant transformation of parathyromatosis to parathyroid carcinoma with invasive growth and distant metastasis.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Parathyroid Carcinoma: From Molecular Pathogenesis and Diagnostic Biomarkers to Targeted Therapeutics.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parathyroid carcinoma (PC) is a rare endocrine malignancy. It accounts for about 1% of all primary hyperparathyroidism (PHPT) cases and 0.005% of all malignancies. PC presents with severe hypercalcemia, often refractory to standard medical treatment, which is crucial for improving patient outcomes. Differentiating PC from atypical parathyroid adenomas and parathyromatosis can be challenging. PC is diagnosed by angio-invasion, lymphatic and perineural invasion, and local malignant invasion with regional and distant metastasis. CD31 positivity on immunohistochemistry, indicating tumor cells within blood vessels in the pseudocapsule (vascular invasion), and a Ki-67% proliferative index of 8% confirm the diagnosis. We describe a 67-year-old man who presented with neck swelling, abdominal pain, and weight loss. Five years prior, he underwent a left inferior parathyroidectomy for a mass, which histological examination identified as clear cell parathyroid adenoma. Three years post-parathyroidectomy, he developed recurrent left-sided neck swelling. Magnetic resonance imaging revealed a lesion with mediastinal extension but no lymph node metastasis. During surgery, the lesion was adherent to the common carotid artery, and histopathological examination confirmed parathyromatosis. Recently, he presented again with new-onset neck swelling, abdominal pain, and weight loss. Biochemical investigations confirmed primary hyperparathyroidism. Invasive growth into surrounding tissues, blood vessels, and nerves, along with lymph node involvement and lung metastasis, with histopathology showing CD31 positivity and a Ki-67% proliferative index of 8%, confirmed the diagnosis of PC. As the tumor was inoperable, hypercalcemia was managed with cinacalcet, resulting in a decline in serum calcium levels. Learning points: Parathyroid carcinoma is one of the rarest malignancies.Parathyromatosis is parathyroid tissue displaced in the neck and mediastinum due to prior surgery or aberrant embryonic development.The diagnosis of parathyroid carcinoma on histopathology is based on:Local invasion into adjacent structures, such as adipose tissues/skeletal muscle bundles.Loco-regional invasion-lymphatic (D240 IHC+), angio-invasion (CD31 IHC+), and perineural invasion.Nuclear pleomorphism, hyperchromatic nuclei, and increased mitosis (high Ki-67 proliferative index of >5%).Regional and distant metastasis in the lungs and other organs.Management of severe hypercalcemia is crucial for improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.